T. Rowe Price Associates
PHAT icon

T. Rowe Price Associates’s Phathom Pharmaceuticals PHAT Stock Holding History

T. Rowe Price Associates’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$714K Buy
65,722
+13,269
+25% +$151K ﹤0.01% 2462
2026
Q1 		$583K Buy
52,453
+15,382
+41% +$194K ﹤0.01% 2381
2025
Q4 		$616K Buy
37,071
+5,152
+16% +$73.6K ﹤0.01% 2298
2025
Q3 		$376K Buy
31,919
+1,815
+6% +$18.7K ﹤0.01% 2497
2025
Q2 		$289K Buy
30,104
+3,091
+11% +$17.1K ﹤0.01% 2548
2025
Q1 		$170K Buy
27,013
+1,372
+5% +$8.33K ﹤0.01% 2706
2024
Q4 		$209K Buy
25,641
+4,592
+22% +$56.9K ﹤0.01% 2659
2024
Q3 		$381K Buy
21,049
+474
+2% +$6.63K ﹤0.01% 2369
2024
Q2 		$212K Buy
20,575
+1,002
+5% +$10.3K ﹤0.01% 2575
2024
Q1 		$208K Buy
19,573
+2,172
+12% +$18.4K ﹤0.01% 2609
2023
Q4 		$159K Buy
17,401
+4,007
+30% +$34.5K ﹤0.01% 2609
2023
Q3 		$139K Sell
13,394
-38
-0.3% -$521 ﹤0.01% 2592
2023
Q2 		$193K Sell
13,432
-1,636
-11% -$18.9K ﹤0.01% 2545
2023
Q1 		$108K Buy
15,068
+118
+0.8% +$1.04K ﹤0.01% 2670
2022
Q4 		$168K Buy
14,950
+315
+2% +$3.25K ﹤0.01% 2587
2022
Q3 		$163K Buy
14,635
+4,295
+42% +$40.9K ﹤0.01% 2608
2022
Q2 		$87K Buy
+10,340
New +$106K ﹤0.01% 2783
2021
Q1 		– Sell
-81,021
Closed -$2.69M – 2868
2020
Q4 		$2.69M Sell
81,021
-59,441
-42% -$2.41M ﹤0.01% 1551
2020
Q3 		$5.15M Sell
140,462
-36,906
-21% -$1.28M ﹤0.01% 1399
2020
Q2 		$5.84M Buy
+177,368
New +$6.81M ﹤0.01% 1369

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Associates's PHAT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Phathom Pharmaceuticals (PHAT) stake by 25% in Q2 2026, buying an estimated $151K and bringing the position to 65,722 shares worth $714K. The position accounts for ﹤0.01% of the portfolio, ranked #2462.

T. Rowe Price Associates first reported a position in PHAT in Q2 2020 and has held it in 20 quarters since. The position peaked at $5.84M in Q2 2020. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • T. Rowe Price Associates held 65,722 shares of Phathom Pharmaceuticals worth $714K as of Q2 2026.
  • T. Rowe Price Associates bought 13,269 Phathom Pharmaceuticals shares in Q2 2026, an estimated $151K.
  • Phathom Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2462 holding.
  • T. Rowe Price Associates first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Phathom Pharmaceuticals position peaked at $5.84M in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.